16.41
+6.35%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ultragenyx Pharmaceutical
From its filings with the US Securities and Exchange Commission
Ultragenyx Pharmaceutical is based in Novato, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RARE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $673.0m and a net loss of $575.0m. At that date it held total assets of $1.53bn and shareholders' equity of −$80.0m. By region, North America accounted for 56.0%, followed by Latin America [Member] at 25.3% and EMEA [Member] at 16.0%.
We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph.D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics. Our strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Our current approved therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates.
Crysvita is a fully human monoclonal antibody administered via subcutaneous injection, that targets fibroblast growth factor 23, or FGF23, developed for the treatment of XLH. XLH is a rare, hereditary, progressive, and lifelong musculoskeletal disorder characterized by renal phosphate wasting caused by excess FGF23 production. There are approximately 48,000 patients with XLH in the developed world, including approximately 36,000 adults and 12,000 children. Crysvita is the only approved treatment that addresses the underlying cause of XLH.
Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Jan 2014
- Employees
- 1,371
- Website
- ultragenyx.com ↗
- Head office
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Daniel WelchIndependent Chairman of the Board$500,134
- Dr. Emil KakkisPresident, Chief Executive Officer, Director, since 2010$13.7m
- Mr. Howard HornChief Financial Officer, Executive Vice President, Corporate Strategy$4.3m
- Mr. Dennis HuangExecutive Vice President, Chief Technical Operations Officer, Gene Therapy Operations$4.2m
- Dr. Eric CrombezExecutive Vice President, Chief Medical Officer$4.3m
- Mr. Erik HarrisExecutive Vice President, Chief Commercial Officer$4.3m
- Mr. Eric OlsonChief Business Officer, Executive Vice President
- Ms. Karah ParschauerExecutive Vice President, Chief Legal Officer, Corporate Affairs$4.0m
- Mr. John PinionChief Quality Officer, Executive Vice President - Translational Sciences$4.1m
- Dr. Deborah DunsireIndependent Director$466,759
- Mr. Matthew FustIndependent Director$480,134
- Mr. Michael NarachiIndependent Director$481,884
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 68
- Environment
- 44
- Social
- 99
- Governance
- 60
- Women in the workforce
- 55.7%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ultragenyx Pharmaceutical Inc, a leading biopharmaceutical company, possesses several strengths that contribute to its success:
Weaknesses
- Despite its strengths, Ultragenyx Pharmaceutical Inc also faces certain weaknesses:
Opportunities
- Ultragenyx Pharmaceutical Inc can leverage the following opportunities to enhance its market position:
Threats
- Ultragenyx Pharmaceutical Inc should be mindful of the following threats that could impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.